Nav: Home

Limited supply may scupper proposals to use antimalarials to ward off Covid-19

April 02, 2020

Limited global supplies may scupper proposals to use the antimalarial drugs, chloroquine and hydroxychloroquine, to lessen the symptoms of Covid-19 infection or ward it off altogether, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases.

The results of preliminary lab tests have prompted scientists to propose that these drugs be used to treat patients with pneumonia caused by Covid-19 infection. This approach has already been included in Chinese guidelines on how best to manage the disease.

Various studies over the past decade have shown that antimalarial drugs can lessen the impact of viral infections, including Covid-19. And clinical trials are now under way to see whether these drugs might help ward off the disease altogether.

Chloroquine and hydroxychloroquine have been used to treat autoimmune disease, including rheumatic diseases, since the 1940s, and have proved safe and well tolerated in most cases, say the authors.

Side effects are generally mild to moderate, with serious complications, such as retinal and cardiac damage, rare and related to cumulative doses over a long period of time.

There is an ethical issue, however, as there is as yet no hard evidence from clinical trials that these drugs can prevent the spread of Covid-19, they point out.

"Is it permissible to take a controlled risk in the event of a pandemic?" they ask. "In such a case: would it be reasonable to consider antimalarials as primary prophylaxis in healthy subjects living in highest risk regions or, at least, to use them in those testing positive for Covid-19, but still asymptomatic?"

The safety and effectiveness of these drugs makes them good candidates for mass preventive treatment programmes, they add, and scientists seem to be leaning towards adopting this approach.

But, conclude the authors: "If mass prophylaxis was accepted as an option worldwide, this would raise the question of whether there is enough supply of [chloroquine] and [hydroxychloroquine] to support this approach."

The European League Against Rheumatism (EULAR), which co-owns the Annals of the Rheumatic Diseases with BMJ, says that the use of these drugs to tackle Covid-19 could have serious implications for people with rheumatic diseases across Europe.

EULAR President, Professor Iain McInnes, says that global efforts to boost the evidence base for the use of these antimalarial drugs to treat Covid-19 are extremely welcome.

But he adds: "EULAR is concerned, however, that the diversion of drug supplies away from people with rheumatic and musculoskeletal diseases may compromise the health of this important and sizeable group of patients in Europe and beyond."

EULAR's patient membership group (PARE) is now calling on the manufacturers of these drugs to rapidly increase production to meet the projected surge in demand.

"A balanced approach that meets the imperatives of the ongoing pandemic, but which also takes account of the needs of patients already taking these drugs is essential," insists Professor McInnes.
-end-
Peer reviewed? No

Evidence type: Observational

Subjects: People

BMJ

Related Clinical Trials Articles:

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.
Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.
Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.